臨床試験用イメージング市場

出版:MarketsandMarkets

Clinical Trial Imaging Market by Software & Services(Operational Imaging, Read Analysis), Modality(CT, MRI, X-ray, PET, Ultrasound, ECHO), Therapeutic Areas(Infectious, Oncology, CNS, CVS), End user(Pharma, biotechnology, CRO) – Global Forecast to 2026

種別 英文調査報告書
出版 MarketsandMarkets
出版年月 2021年7 月
ページ数 199
図表数 236

レポート目次  お問合せ

臨床試験用イメージング市場 ソフトウェアとサービス(オペレーショナルイメージング、読み取り分析)、モダリティ(CT、MRI、X線、PET、超音波、ECHO)、治療領域(感染症、腫瘍学、CNS、CVS)、エンドユーザー(製薬、バイオテクノロジー、CRO)
The global clinical trial imaging market is projected to reach USD 1.4billion by 2026 from USD 1.0billion in 2021, at a CAGR of 7.6% during the forecast period. Market growth is driven by factors such as the growth in the pharmaceutical and biotechnology industries, increase in R&D spending and increasing number of CROs. On the other hand, the high implementation cost of imaging system and high cost of clinical trials are the major factors hampering the growth of this market.
“The service segment accounted for the highest growth rate in theclinical trial imaging market, by product, during the forecast period”
Theclinical trial imaging market is segmented into services and software based on product and service. In 2020, the service segment accounted for the highest growth rate in the clinical trial imaging market. increase in R&D spending and growth in pharmaceutical and biotechnology industries are major factor contributing to the growth of this segment.
“Medical device manufacturers segment accounted for the highest CAGR”
Based onend user, the clinical trial imaging market is segmented intopharmaceutical companies, biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes and other end users. In 2020, the medical device manufacturers segment accounted for the highest growth rate. This can be attributed to theincreasing number of CROs, increase R&D spending and growth in the pharmaceutical and biotechnology industries.
“Asia Pacific: The fastest-growing regionclinical trial imaging market”
The global clinical trial imaging market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period.Factors such as the growth in the pharmaceutical and biotechnology industries and increase in R&D spending are driving the growth of the clinical trial imaging market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• ICON plc. (Ireland)
• BioTelemetry Inc. (US)
• Biomedical Systems Corporation (US)
• Medpace Holdings, Inc. (US)
• IXICO plc. (UK)
• Resonance Health Ltd. (Australia)
• Radiant Sage LLC. (US)
• BioClinica Inc. (US)
• Intrinsic Imaging LLC. (US)
• Cardiovascular Imaging Technologies LLC. (US)
• Medical Metrics Inc. (US)
• Prism Clinical Imaging, Inc. (US)
• Boston Imaging Core Lab LLC. (US)
• anagram 4 clinical trials (Spain)
• Lyscaut Medical Imaging Company (Belgium)
• Calyx Group (UK)
• Bioseptive Inc. (Canada)
• ProScan Imaging LLC. (US)
• Micron Inc. (Japan)
• Imaging Endpoints LI, LLC (US)
• Perspectum Ltd. (UK)
• PharmtraceklinischeEntwicklung GmbH (Germany)
• WorldCare Clinical, LLC (US)
Research Coverage:
This report provides a detailed picture of the global clinical trial imaging market. It aims at estimating the size and future growth potential of the market across different segments, such as product and service,modality, therapeutic area, end userand region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.


目次

1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 33
1.2.2 MARKETS COVERED 34
FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION 34
1.2.3 YEARS CONSIDERED FOR THE STUDY 34
1.3 CURRENCY 35
1.4 LIMITATIONS 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.2 RESEARCH APPROACH 37
FIGURE 2 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 37
2.2.1 SECONDARY DATA 38
2.2.1.1 Key data from secondary sources 38
2.2.2 PRIMARY DATA 39
2.2.2.1 Key data from primary sources 39
2.2.2.2 Key industry insights 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.3 MARKET SIZE ESTIMATION 41
2.3.1 BOTTOM-UP APPROACH 41
FIGURE 4 CLINICAL TRIAL IMAGING MARKET: BOTTOM-UP APPROACH 42
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
2.3.2 TOP-DOWN APPROACH 42
FIGURE 6 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 42
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 43
FIGURE 7 DATA TRIANGULATION METHODOLOGY 43
2.5 ASSUMPTIONS FOR THE STUDY 44
2.6 GROWTH RATE ASSUMPTIONS 44
2.7 LIMITATIONS 45
2.8 RISK ASSESSMENT 45
2.9 COVID-19 HEALTH ASSESSMENT 45
2.10 COVID-19 ECONOMIC ASSESSMENT 46
2.10.1 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 46
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY 46
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 47
2.10.2 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE CLINICAL TRIAL IMAGING MARKET 48
3 EXECUTIVE SUMMARY 49
FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT AND SERVICE,
2021 VS. 2026 (USD MILLION) 49
FIGURE 11 CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2021 VS. 2026 (USD MILLION) 50
FIGURE 12 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2021 VS. 2026 (USD MILLION) 50
FIGURE 13 CLINICAL TRIAL IMAGING MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 51
FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 51
4 PREMIUM INSIGHTS 53
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 53
FIGURE 15 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH 53
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 53
FIGURE 16 SERVICES WILL CONTINUE TO DOMINATE THE MARKET IN 2026 53
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2021 VS. 2026 54
FIGURE 17 COMPUTED TOMOGRAPHY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 54
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2021 VS. 2026 54
FIGURE 18 ONCOLOGY IS THE LARGEST SEGMENT IN THE CLINICAL TRIAL IMAGING MARKET BY THERAPEUTIC AREA 54
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2021 VS. 2026 55
FIGURE 19 PHARMACEUTICAL COMPANIES FORM THE LARGEST END USERS OF THE CLINICAL TRIAL IMAGING MARKET 55
4.6 CLINICAL TRIAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE CLINICAL TRIAL IMAGING MARKET DURING THE FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing R&D spending 57
5.2.1.2 Growth in the pharmaceutical and biotechnology industries 57
5.2.1.3 Increasing number of CROs 57
5.2.2 RESTRAINTS 58
5.2.2.1 High implementation cost of imaging systems 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Developing countries 58
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals 58
5.2.4 CHALLENGES 59
5.2.4.1 High cost of clinical trials 59
5.3 IMPACT OF COVID-19 ON THE CLINICAL TRIAL IMAGING MARKET 59
5.4 PRICING ANALYSIS 59
TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2021) 59
5.5 PATENT ANALYSIS 60
5.6 TRADE ANALYSIS 60
5.6.1 TRADE ANALYSIS FOR X-RAY APPARATUSES 60
TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 60
TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 61
5.6.2 TRADE ANALYSIS FOR CT APPARATUSES 61
TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 61
TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY,
2016–2020 (USD MILLION) 61
5.7 VALUE CHAIN ANALYSIS 62
FIGURE 22 MAJOR VALUE IS ADDED DURING THE DEVELOPMENT AND PROCUREMENT PHASES 62
5.8 SUPPLY CHAIN ANALYSIS 63
FIGURE 23 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 63
5.9 ECOSYSTEM ANALYSIS OF THE CLINICAL TRIAL IMAGING MARKET 64
FIGURE 24 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 64
5.9.1 ROLE IN THE ECOSYSTEM 64
5.10 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 6 CLINICAL TRIAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 THREAT OF NEW ENTRANTS 65
5.10.2 THREAT OF SUBSTITUTES 65
5.10.3 BARGAINING POWER OF BUYERS 65
5.10.4 BARGAINING POWER OF SUPPLIERS 65
5.10.5 DEGREE OF COMPETITION 66
5.11 PESTLE ANALYSIS 66
5.12 REGULATORY LANDSCAPE 67
5.12.1 NORTH AMERICA 67
5.12.1.1 US 67
5.12.1.2 Canada 67
5.12.2 EUROPE 67
5.12.3 ASIA PACIFIC 67
5.12.3.1 Japan 67
5.12.3.2 India 68
5.12.3.3 China 68
5.12.4 LATIN AMERICA 68
5.12.4.1 Brazil 69
5.12.4.2 Mexico 69
5.12.5 MIDDLE EAST 69
5.12.6 AFRICA 69
5.13 TECHNOLOGY ANALYSIS 70
5.14 DISRUPTIVE TECHNOLOGIES IN THE CLINICAL TRIAL IMAGING MARKET 70
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR THE CLINICAL TRIAL IMAGING MARKET 70
FIGURE 25 REVENUE SHIFT FOR THE CLINICAL TRIAL IMAGING MARKET 70
6 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE 71
6.1 INTRODUCTION 72
TABLE 7 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 72
TABLE 8 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 72
6.2 SERVICES 72
TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2016–2019 (USD MILLION) 73
TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
2020–2026 (USD MILLION) 73
TABLE 11 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 73
TABLE 12 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 74
6.2.1 OPERATIONAL IMAGING SERVICES 74
6.2.1.1 The rising number of CROs supports the growth of this segment 74
FIGURE 26 INDUSTRY INSIGHTS ON OPERATIONAL IMAGING SERVICES 74
TABLE 13 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 75
TABLE 14 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 75
6.2.2 READ ANALYSIS SERVICES 75
6.2.2.1 Increased number of clinical trials is the major factor supporting the growth of this segment 75
TABLE 15 READ ANALYSIS SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION) 76
TABLE 16 READ ANALYSIS SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION) 76
6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES 76
6.2.3.1 Need for continuous technical support to drive this segment 76
TABLE 17 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 77
TABLE 18 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 77
6.2.4 TRIAL DESIGN & CONSULTING SERVICES 77
6.2.4.1 Rising R&D spending and support for clinical trials will prompt companies to outsource trial design processes 77
TABLE 19 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION,
2016–2019 (USD MILLION) 78
TABLE 20 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION,
2020–2026 (USD MILLION) 78
6.3 SOFTWARE 78
6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE SUPPORT ITS ADOPTION 78
TABLE 21 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
2016–2019 (USD MILLION) 79
TABLE 22 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
2020–2026 (USD MILLION) 79
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 80
7.1 INTRODUCTION 81
TABLE 23 CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 81
TABLE 24 CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 81
7.2 COMPUTED TOMOGRAPHY 82
7.2.1 QUICK RESULTS AND NO VISIBLE SIDE-EFFECTS DRIVE THE ADOPTION OF CT 82
TABLE 25 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY REGION, 2016–2019 (USD MILLION) 82
TABLE 26 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY REGION, 2020–2026 (USD MILLION) 83
7.3 MAGNETIC RESONANCE IMAGING 83
7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET GROWTH 83
TABLE 27 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2016–2019 (USD MILLION) 84
TABLE 28 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2020–2026 (USD MILLION) 84
7.4 ULTRASOUND 84
7.4.1 ULTRASOUND IMAGING IS SAFER THAN CT AND MRI IMAGING 84
TABLE 29 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
2016–2019 (USD MILLION) 85
TABLE 30 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
2020–2026 (USD MILLION) 85
7.5 POSITRON EMISSION TOMOGRAPHY 85
7.5.1 PET IS A PART OF NUCLEAR MEDICINE IMAGING 85
TABLE 31 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION,
2016–2019 (USD MILLION) 86
TABLE 32 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION,
2020–2026 (USD MILLION) 86
7.6 X-RAY 87
7.6.1 X-RAY IS MOST COMMONLY USED IN BONE, CHEST, AND DENTAL IMAGING 87
TABLE 33 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
2016–2019 (USD MILLION) 87
TABLE 34 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
2020–2026 (USD MILLION) 87
7.7 ECHOCARDIOGRAPHY 88
7.7.1 ECHO-DOPPLER PARAMETERS ARE CONSIDERED ACCEPTABLE AS A PROOF OF CONCEPT OF TREATMENT IN PHASE-II TRIALS 88
TABLE 35 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2016–2019 (USD MILLION) 88
TABLE 36 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2020–2026 (USD MILLION) 88
7.8 OTHER MODALITIES 89
TABLE 37 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2016–2019 (USD MILLION) 89
TABLE 38 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2020–2026 (USD MILLION) 90
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 91
8.1 INTRODUCTION 92
TABLE 39 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2016–2019 (USD MILLION) 92
TABLE 40 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2016–2019 (USD MILLION) 93
TABLE 42 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION,
2020–2026 (USD MILLION) 94
8.3 INFECTIOUS DISEASES 94
8.3.1 RISING DRUG DISCOVERY ACTIVITY SUPPORTS MARKET GROWTH 94
TABLE 43 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016–2019 (USD MILLION) 94
TABLE 44 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2026 (USD MILLION) 95
8.4 NEUROLOGY 95
8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE SEGMENT GROWTH 95
TABLE 45 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
2016–2019 (USD MILLION) 96
TABLE 46 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
2020–2026 (USD MILLION) 96
8.5 CARDIOVASCULAR SYSTEM DISORDERS 96
8.5.1 HIGH MORTALITY RATE OF CVD HAS DRIVEN FOCUS ON THERAPEUTICS AND CLINICAL TRIALS 96
TABLE 47 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2016–2019 (USD MILLION) 97
TABLE 48 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2026 (USD MILLION) 97
8.6 ENDOCRINOLOGY 97
8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH 97
TABLE 49 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2016–2019 (USD MILLION) 98
TABLE 50 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2020–2026 (USD MILLION) 98
8.7 IMMUNOLOGICAL DISORDERS 99
8.7.1 ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES ARE HIGHLY COMMON AILMENTS GLOBALLY 99
TABLE 51 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2016–2019 (USD MILLION) 99
TABLE 52 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2020–2026 (USD MILLION) 99
8.8 OTHER THERAPEUTIC AREAS 100
TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2016–2019 (USD MILLION) 100
TABLE 54 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2020–2026 (USD MILLION) 101
9 CLINICAL TRIAL IMAGING MARKET, BY END USER 102
9.1 INTRODUCTION 103
TABLE 55 CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 103
TABLE 56 CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 103
9.2 PHARMACEUTICAL COMPANIES 104
9.2.1 INCREASING R&D ACTIVITIES BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH FOR THIS SEGMENT 104
TABLE 57 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES,
BY REGION, 2016–2019 (USD MILLION) 104
TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES,
BY REGION, 2020–2026 (USD MILLION) 105
9.3 BIOTECHNOLOGY COMPANIES 105
9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE GROWTH 105
TABLE 59 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2019–2020 106
TABLE 60 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES,
BY REGION, 2016–2019 (USD MILLION) 106
TABLE 61 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES,
BY REGION, 2020–2026 (USD MILLION) 107
9.4 MEDICAL DEVICE MANUFACTURERS 107
9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO DRIVE MARKET GROWTH 107
TABLE 62 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2016–2019 (USD MILLION) 108
TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2020–2026 (USD MILLION) 108
9.5 CONTRACT RESEARCH ORGANIZATIONS 108
9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET GROWTH 108
TABLE 64 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2016–2019 (USD MILLION) 109
TABLE 65 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2026 (USD MILLION) 110
9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 110
9.6.1 INCREASING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH 110
TABLE 66 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2016–2019 (USD MILLION) 111
TABLE 67 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET, BY REGION, 2020–2026 (USD MILLION) 111
9.7 OTHER END USERS 112
TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2016–2019 (USD MILLION) 112
TABLE 69 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2020–2026 (USD MILLION) 112
10 CLINICAL TRIAL IMAGING MARKET, BY REGION 113
10.1 INTRODUCTION 114
TABLE 70 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2016–2019 (USD MILLION) 114
TABLE 71 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020–2026 (USD MILLION) 114
10.2 NORTH AMERICA 115
FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 115
TABLE 72 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 116
TABLE 73 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 116
TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 116
TABLE 75 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 117
TABLE 76 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 117
TABLE 77 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 117
TABLE 78 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 118
TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 118
10.2.1 US 118
10.2.1.1 Increased investment in the biopharmaceutical industry in the US to favor market growth 118
TABLE 80 US: PRODUCT APPROVALS IN THE CLINICAL TRIAL IMAGING SPACE 119
TABLE 81 US: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 119
TABLE 82 US: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 119
TABLE 83 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 120
TABLE 84 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 120
TABLE 85 US: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 121
TABLE 86 US: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 121
10.2.2 CANADA 121
10.2.2.1 Increase in per capita healthcare spending to drive the clinical trial imaging market in Canada 121
TABLE 87 CANADA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 122
TABLE 88 CANADA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 122
TABLE 89 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 122
TABLE 90 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 123
TABLE 91 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 123
TABLE 92 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 123
10.3 EUROPE 124
TABLE 93 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 124
TABLE 94 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 124
TABLE 95 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 125
TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 125
TABLE 97 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 125
TABLE 98 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 126
TABLE 99 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 126
TABLE 100 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 126
10.3.1 GERMANY 127
10.3.1.1 Germany is the largest & fastest-growing market for clinical trial imaging in Europe 127
TABLE 101 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 127
TABLE 102 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 127
TABLE 103 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 128
TABLE 104 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 128
TABLE 105 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 129
TABLE 106 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 129
10.3.2 UK 129
10.3.2.1 Rising research investments to drive the market growth in the UK 129
TABLE 107 UK: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 130
TABLE 108 UK: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 130
TABLE 109 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 130
TABLE 110 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 131
TABLE 111 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 131
TABLE 112 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 131
10.3.3 FRANCE 132
10.3.3.1 Rising R&D expenditure to drive market growth in France 132
TABLE 113 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 132
TABLE 114 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 132
TABLE 115 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 133
TABLE 116 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 133
TABLE 117 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 134
TABLE 118 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 134
10.3.4 ITALY 134
10.3.4.1 Increase R&D spending on healthcare to drive market growth in this region 134
TABLE 119 ITALY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 135
TABLE 120 ITALY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 135
TABLE 121 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 135
TABLE 122 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 136
TABLE 123 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 136
TABLE 124 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 136
10.3.5 SPAIN 137
10.3.5.1 Growth of pharmaceutical companies 137
TABLE 125 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 137
TABLE 126 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 137
TABLE 127 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 138
TABLE 128 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 138
TABLE 129 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 139
TABLE 130 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 139
10.3.6 REST OF EUROPE 139
TABLE 131 ROE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 140
TABLE 132 ROE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 140
TABLE 133 ROE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 140
TABLE 134 ROE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 141
TABLE 135 ROE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 141
TABLE 136 ROE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 141
10.4 ASIA PACIFIC 142
FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 142
TABLE 137 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 143
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 143
TABLE 139 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 143
TABLE 140 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 144
TABLE 141 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 144
TABLE 142 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 144
TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 145
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 145
10.4.1 CHINA 145
10.4.1.1 Increase in research spending to drive market growth 145
TABLE 145 CHINA: KEY MACROINDICATORS 146
TABLE 146 CHINA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 146
TABLE 147 CHINA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 146
TABLE 148 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 147
TABLE 149 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 147
TABLE 150 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 148
TABLE 151 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 148
10.4.2 JAPAN 148
10.4.2.1 Rising population and healthcare expenditure are favorable factors in Japan 148
TABLE 152 JAPAN: KEY MACROINDICATORS 149
TABLE 153 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 149
TABLE 154 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 149
TABLE 155 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 150
TABLE 156 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 150
TABLE 157 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 151
TABLE 158 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 151
10.4.3 INDIA 151
10.4.3.1 Increased investment in R&D to drive the adoption of clinical trial imaging 151
TABLE 159 INDIA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2016–2019 (USD MILLION) 152
TABLE 160 INDIA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE,
2020–2026 (USD MILLION) 152
TABLE 161 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 153
TABLE 162 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 153
TABLE 163 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 154
TABLE 164 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 154
10.4.4 REST OF ASIA PACIFIC 154
TABLE 165 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 155
TABLE 166 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 155
TABLE 167 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 155
TABLE 168 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 156
TABLE 169 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY END USER
, 2016–2019 (USD MILLION) 156
TABLE 170 ROAPAC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 156
10.5 LATIN AMERICA 157
10.5.1 INCREASING R&D DUE TO DISEASE OUTBREAKS TO SUPPORT MARKET GROWTH 157
TABLE 171 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 157
TABLE 172 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 157
TABLE 173 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2016–2019 (USD MILLION) 158
TABLE 174 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
2020–2026 (USD MILLION) 158
TABLE 175 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2016–2019 (USD MILLION) 159
TABLE 176 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
2020–2026 (USD MILLION) 159
10.6 MIDDLE EAST & AFRICA 160
10.6.1 INCREASED FUNDING AND PARTNERSHIPS IN THE RESEARCH SECTOR TO PROPEL MARKET GROWTH 160
TABLE 177 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION) 160
TABLE 178 MIDDLE EAST AND AFRICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION) 160
TABLE 179 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2016–2019 (USD MILLION) 161
TABLE 180 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020–2026 (USD MILLION) 161
TABLE 181 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2016–2019 (USD MILLION) 162
TABLE 182 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020–2026 (USD MILLION) 162
11 COMPETITIVE LANDSCAPE 163
11.1 OVERVIEW 163
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 163
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET 163
TABLE 183 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CLINICAL TRIAL IMAGING PRODUCT MANUFACTURING COMPANIES 163
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 165
FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET 165
11.4 MARKET SHARE ANALYSIS 166
FIGURE 30 CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER (2020) 166
TABLE 184 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 166
11.5 COMPANY EVALUATION QUADRANT 167
11.5.1 STARS 167
11.5.2 EMERGING LEADERS 167
11.5.3 PERVASIVE PLAYERS 167
11.5.4 PARTICIPANTS 167
FIGURE 31 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION QUADRANT, 2020 168
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020) 168
11.6.1 PROGRESSIVE COMPANIES 168
11.6.2 STARTING BLOCKS 169
11.6.3 RESPONSIVE COMPANIES 169
11.6.4 DYNAMIC COMPANIES 169
FIGURE 32 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 169
11.7 COMPETITIVE BENCHMARKING 170
FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CLINICAL TRIAL IMAGING MARKET 170
TABLE 185 COMPANY PRODUCT FOOTPRINT 170
TABLE 186 COMPANY GEOGRAPHICAL FOOTPRINT 170
11.8 COMPETITIVE SCENARIO 171
11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 171
TABLE 187 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 171
11.8.2 DEALS 171
TABLE 188 KEY DEALS 171
12 COMPANY PROFILES 172
12.1 KEY PLAYERS 172
(Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats)*
12.1.1 ICON PLC. 172
TABLE 189 ICON PLC.: BUSINESS OVERVIEW 172
FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2020) 172
12.1.2 BIOTELEMETRY INC. 175
TABLE 190 BIOTELEMETRY INC.: BUSINESS OVERVIEW 175
FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2020) 175
12.1.3 BIOMEDICAL SYSTEMS CORPORATION (A PART OF ERT CLINICAL) 177
TABLE 191 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 177
12.1.4 MEDPACE HOLDINGS INC. 178
TABLE 192 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 178
FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2020) 178
12.1.5 IXICO PLC. 180
TABLE 193 IXICO PLC.: BUSINESS OVERVIEW 180
FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2020) 180
12.1.6 RESONANCE HEALTH LTD. 183
TABLE 194 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW 183
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2020) 183
12.1.7 RADIANT SAGE 186
TABLE 195 RADIANT SAGE: BUSINESS OVERVIEW 186
12.1.8 BIOCLINICA INC. 187
TABLE 196 BIOCLINICA: BUSINESS OVERVIEW 187
12.1.9 INTRINSIC IMAGING 189
TABLE 197 INTRINSIC IMAGING: BUSINESS OVERVIEW 189
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES 190
TABLE 198 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW 190
12.2 OTHER PLAYERS 191
12.2.1 MEDICAL METRICS 191
12.2.2 PRISM CLINICAL IMAGING 191
12.2.3 BOSTON IMAGING CORE LAB 192
12.2.4 ANAGRAM 4 CLINICAL TRIALS 192
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY 193
12.2.6 CALYX GROUP 193
12.2.7 BIOSPECTIVE 194
12.2.8 PROSCAN IMAGING 194
12.2.9 MICRON 195
12.2.10 IMAGING ENDPOINTS LI LLC. 196
12.2.11 PERSPECTUM 196
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG 197
12.2.13 WORLDCARE CLINICAL 197
*Details on Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats might not be captured in case of unlisted companies.
13 APPENDIX 198
13.1 INDUSTRY INSIGHTS 198
13.2 DISCUSSION GUIDE 199
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 203
13.4 AVAILABLE CUSTOMIZATIONS 205
13.5 RELATED REPORTS 205
13.6 AUTHOR DETAILS 206


お問合せフォーム

    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com